Literature DB >> 2678039

Amplification, rearrangement, and elevated expression of c-myc in the human prostatic carcinoma cell line LNCaP.

A Nag1, R G Smith.   

Abstract

We have investigated the structure and expression of the c-myc proto-oncogene in DNA isolated from the immortal cell line LNCaP. This cell line was derived from a lymph node metastasis of human prostate cancer. Msp I digest of LNCaP DNA when hybridized to a human c-myc probe showed a 1.45 kb band of intensity about two-fold greater than that observed in normal lymphocytes. In addition, the LNCaP cells contain rearranged and amplified c-myc structures which are not present in normal lymphocytes. Quantitation of these bands by scanning densitometry is consistent with an approximately 10-fold amplification of c-myc. To determine whether this amplification was accompanied by increased expression, RNA was isolated from these cells and compared to RNA isolated from a control cell line in which c-myc was not amplified. Northern blot analysis showed that the RNA transcripts from LNCaP cells were approximately 50-fold higher. Although androgens modulate the cell growth of LNCaP, there was no change in the level of c-myc RNA transcripts in serum-free medium in the presence or absence of androgens. Further investigation to determine whether altered structure, amplification, and overexpression of c-myc constitute a common characteristic of metastatic human prostate cancer might prove profitable in understanding this disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2678039     DOI: 10.1002/pros.2990150205

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  11 in total

1.  Differential expression of the ccn3 (nov) proto-oncogene in human prostate cell lines and tissues.

Authors:  M Maillard; B Cadot; R Y Ball; K Sethia; D R Edwards; B Perbal; R Tatoud
Journal:  Mol Pathol       Date:  2001-08

2.  Cultured human atherosclerotic plaque smooth muscle cells retain transforming potential and display enhanced expression of the myc protooncogene.

Authors:  J L Parkes; R R Cardell; F C Hubbard; D Hubbard; A Meltzer; A Penn
Journal:  Am J Pathol       Date:  1991-03       Impact factor: 4.307

3.  Different patterns of DNA alterations detected by restriction landmark genomic scanning in heterogeneous prostate carcinomas.

Authors:  N Konishi; Y Hiasa; M Nakamura; Y Kitahori; K Matsubara; H Nagai
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

4.  Inhibition of 5-lipoxygenase selectively triggers disruption of c-Myc signaling in prostate cancer cells.

Authors:  Sivalokanathan Sarveswaran; Debrup Chakraborty; Dhananjay Chitale; Rosalie Sears; Jagadananda Ghosh
Journal:  J Biol Chem       Date:  2014-12-24       Impact factor: 5.157

5.  Leelamine suppresses cMyc expression in prostate cancer cells in vitro and inhibits prostate carcinogenesis in vivo.

Authors:  Krishna B Singh; Eun-Ryeong Hahm; Shivendra V Singh
Journal:  J Cancer Metastasis Treat       Date:  2021-03-26

6.  Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1.

Authors:  Soo-Young Kang; Ole J Halvorsen; Karsten Gravdal; Nandita Bhattacharya; Jung Min Lee; Nathan W Liu; Brian T Johnston; Adam B Johnston; Svein A Haukaas; Kristie Aamodt; Sun Yoo; Lars A Akslen; Randolph S Watnick
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-06       Impact factor: 11.205

7.  Gene amplifications in advanced-stage human prostate cancer.

Authors:  G Fournier; A Latil; Y Amet; J H Abalain; A Volant; P Mangin; H H Floch; R Lidereau
Journal:  Urol Res       Date:  1995

8.  U94 alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis of prostate cancer cell line PC3.

Authors:  Ekwere T Ifon; Alan L Y Pang; Warren Johnson; Kathleen Cashman; Sharon Zimmerman; Sumitra Muralidhar; Wai-Yee Chan; John Casey; Leonard Jason Rosenthal
Journal:  Cancer Cell Int       Date:  2005-06-22       Impact factor: 5.722

9.  A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer.

Authors:  Shanshan Bai; Subing Cao; Lianjin Jin; Margaret Kobelski; Blake Schouest; Xiaojie Wang; Nathan Ungerleider; Melody Baddoo; Wensheng Zhang; Eva Corey; Robert L Vessella; Xuesen Dong; Kun Zhang; Xianghui Yu; Erik K Flemington; Yan Dong
Journal:  Oncogene       Date:  2019-02-28       Impact factor: 9.867

10.  A novel metabolic function of Myc in regulation of fatty acid synthesis in prostate cancer.

Authors:  Krishna B Singh; Eun-Ryeong Hahm; Su-Hyeong Kim; Stacy G Wendell; Shivendra V Singh
Journal:  Oncogene       Date:  2020-11-16       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.